- The FDA has accepted for review, BioXcel Therapeutics Inc's BTAI marketing application for BXCL501, an orally dissolving thin film formulation of dexmedetomidine.
- The application covers the acute treatment of agitation associated with schizophrenia and bipolar disorders I and II.
- The agency's target action date is January 5, 2022.
- The FDA does not plan to hold an advisory committee meeting to discuss the application.
- Dexmedetomidine is a selective alpha-2a receptor agonist for the treatment of agitation and opioid withdrawal symptoms.
- Price Action: BTAI shares are up 1.4% at $32.2 during the premarket session on the last check Wednesday.
- Related content: Benzinga's Full FDA Calendar
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
